Efficacy and Safety of Poly-L-lactic Acid for Midface Rejuvenation: A 12-Month Split-face Controlled Evaluation With 3D Imaging and Patient-reported Outcomes
Top Cited Papers
- 9 February 2026
- journal article
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal
- Vol. 46 (6) , 663-671
Abstract
Background: Poly-L-lactic acid (PLLA) is a biostimulatory injectable that restores midfacial volume through collagen neogenesis rather than gel-based filling. Controlled clinical evidence directly quantifying PLLA's volumetric efficacy remains limited. Objectives: To evaluate the efficacy, safety, and patient-reported outcomes of a Norberg Medical PLLA formulation for midface rejuvenation in a prospective, evaluator-blinded, split-face controlled study. Participants were enrolled between July 2024 and September 2024, with follow-up completed in September 2025. Methods: Ninety-five patients underwent three standardized PLLA sessions on one hemiface and saline placebo on the contralateral side. Each vial contained 150 mg PLLA in spherical microparticles, reconstituted with 5 mL sterile water without lidocaine. Assessments included Wrinkle Severity Rating Scale (WSRS), Vectra H1 3D volumetry (malar, zygomatic, mandibular), FACE-Q, and Global Aesthetic Improvement Scale (GAIS). Two blinded evaluators rated WSRS. Statistical analysis included paired testing, responder rates (≥1-grade WSRS improvement), and inter-rater reliability (ICC). Results: At 12 months, PLLA-treated sides showed significant WSRS reduction vs baseline and saline control (Δ = −0.68, P < .001). 3D analysis confirmed sustained volumetric enhancement across all midface subunits. Inter-rater reliability was excellent (ICC = 0.91), and 82.1% achieved ≥1-grade WSRS improvement. Patient satisfaction remained high, mirroring objective findings. Adverse events were mild and transient, with no granulomas, nodules, or vascular events recorded. Conclusions: Controlled split-face evaluation demonstrated that standardized PLLA treatment yields measurable, long-lasting midfacial volume restoration with excellent safety and high patient satisfaction. No granulomas or delayed-onset nodules were observed in this 12-month, 95-patient cohort, supporting a favorable safety profile for this PLLA formulation under these study conditions. Level of Evidence: 2 (Therapeutic): For image description, please refer to the figure legend and surrounding text.Keywords
This publication has 12 references indexed in Scilit:
- Pilot Study: Efficacy and Safety of Polycaprolactone Collagen Stimulator for Middle Third of the FacePlastic and Reconstructive Surgery - Global Open, 2025
- Poly-L-Lactic Acid in Aesthetic Dermatology: A Decade Beyond Volume Restoration Toward Regenerative BiostimulationAesthetic Surgery Journal, 2025
- Impact of Poly-L-Lactic Acid Reconstitution on the Neocollagenesis ProfileAesthetic Plastic Surgery, 2025
- In Vivo Effectiveness of Poly-L-Lactic Acid Microsphere Dermal Fillers in Stimulating Collagen SynthesisAesthetic Plastic Surgery, 2025
- Safety and effectiveness results of an innovative injectable poly‐L‐lactic acid‐based collagen stimulator (Lanluma®)—Clinical outcomes at 9 months in a post‐market studyJournal of Cosmetic Dermatology, 2024
- Application of PLLA (Poly-L-Lactic acid) for rejuvenation and reproduction of facial cutaneous tissue in aesthetics: A reviewMedicine, 2024
- Three-Dimensional Analysis of Tear Trough Volume After Lower Blepharoplasty with Midface LiftFacial Plastic Surgery & Aesthetic Medicine, 2023
- Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA)Clinical, Cosmetic and Investigational Dermatology, 2022
- Effect of Hyaluronic Acid and Poly-L-Lactic Acid Dermal Fillers on Collagen Synthesis: An in vitro and in vivo StudyClinical, Cosmetic and Investigational Dermatology, 2020
- Physiochemical Characteristics of Poly-L-Lactic Acid (PLLA)Aesthetic Surgery Journal, 2018